DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of Cephalexin Liquid in Healthy Participants

Information source: Eli Lilly and Company
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Cephalexin (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Eli Lilly and Company

Official(s) and/or principal investigator(s):
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study Director, Affiliation: Eli Lilly and Company


The purpose of this study is to compare two different preparations of an antibiotic called cephalexin to determine if they are essentially the same. The study has two periods. Participants will receive one preparation of cephalexin in each period. At least 7 hours will pass between the study periods. The study is expected to last about 2 days for each participant, not including screening or follow-up.

Clinical Details

Official title: A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 250 mg/5 ml of Cephalexin (Keflex® Liquido Made in Mexico by Eli Lilly y compañía De méxico, s.a. De cv. Vs. Keflex® Liquido Made by Antibioticos do Brasil Ltda for Eli Lilly y compañía de México, s.a. De c.v.) in Fasting Healthy Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Cephalexin Following a Single Dose

Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin Following a Single Dose


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Participation will be voluntary.

- The body mass index of participants should be between 18-27.

- Participants should have a good health status.

- Limits of variation allowed within normal values at screening will be: blood pressure

(seated) up to 139 millimeters of mercury (mm Hg), for systolic, and up to 89 mm Hg for diastolic; heart rate between 60 and 100 beats per minute, and respiratory rate between 14 and 20 breaths per minute.

- Hepatitis B and C and human immunodeficiency virus (HIV) negative.

- Negative drug abuse or alcohol detection test approximately 12 hours before

administering the study medication.

- Negative serum pregnancy test (beta human chorionic gonadotropin) at screening and

urine pregnancy test approximately 12 hours before administering the study medication. Exclusion Criteria:

- Participants with any clinically significant abnormality in their vital sign

constants recorded at screening.

- Sponsor and/or site employees.

- Abnormal 12 lead electrocardiogram (ECG) that in the opinion of the investigator

places the participant at an unacceptable risk for study participation, Bazett corrected QR interval (QTcB) > 470 millisecond (msec) for women and > 450 msec for men.

- Participants with history of cardiovascular, renal, hepatic, muscular, metabolic,

gastrointestinal diseases, including constipation, neurological, endocrine, hematopoietic diseases, or any type of anemia, asthma, mental disease, or other organic abnormalities.

- Participants with a creatinine clearance < 80 mL/min based on the Cockcroft-Gault


- Participants requiring any medication during the study, apart from the medication

which is being studied.

- Participants with history of dyspepsia, gastritis, esophagitis, duodenal or gastric


- Participants who have been exposed to medications known as hepatic enzyme inducers or

inhibitors or who have been taking potentially toxic medications within the 30 days prior.

- Participants who have received any medication, including vitamins (with or without

medical prescription) or herbal-based remedies 30 days (or 7 half-lives) prior to the beginning of the study.

- Participants who have been hospitalized for any condition within six months to the

beginning of the study.

- Participants who have received investigational drugs within the 60 days prior to the


- Participants allergic to any medication, food, or substance.

- Participants who require therapy with nephrotoxic drugs.

- Participants who have donated 450 mL of blood or more within the 60 days prior to the

beginning of the study.

- Participants with history of drug and alcohol abuse.

- Participants with special diet requirement for any cause.

- Participants with positive to pregnancy test or are breastfeeding.

- Participants on hormonal treatment by any route.

- Participants who have not been recorded in the page of the Comisión Federal para la

Protección contra Riesgos Sanitarios (COFEPRIS).

Locations and Contacts

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City 14610, Mexico
Additional Information

Starting date: July 2015
Last updated: August 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017